Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Shows Proof Of Concept For Novel Cholesterol Drug

Executive Summary

An investigational hypolipemic product from Regeneron Pharmaceuticals with a novel mechanism of action appears to have great promise when used in addition to current therapies in familial hypercholesterolemia patients, suggest early data from a small study, but many questions remain.

Advertisement

Related Content

Early Stage Science Watch
Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel